{'fraction_non_alphanumeric': 0.05192719486081371, 'fraction_numerical': 0.04229122055674518, 'mean_word_length': 5.271812080536913, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Impact of bivalirudin on in‐hospital bleeding and six‐month outcomes in octogenarians undergoing percutaneous coronary intervention

Objectives: This study aimed to analyze the impact of replacing heparin with bivalirudin in octogenarians undergoing percutaneous coronary intervention (PCI) on postprocedure hemorrhage and 6‐month mortality. Background: Randomized trials comparing the antithrombin agent bivalirudin with heparin as the intraprocedural anticoagulant identify a reduction in periprocedural bleeding after PCI. Further, the occurrence of such bleeding seems to predict an increased risk of death or myocardial infarction both in‐hospital and at long‐term follow‐up. Importantly, elderly people who are at the greatest risk of post‐PCI bleeding complications are underrepresented in these randomized trials. Methods: From 2000 to 2007, 2,766 consecutive patients from our center who were ≥80 years of age underwent PCI with stent implantation and were included in this analysis. Bivalirudin was used in 1,207 (43.6%) patients and heparin in 1,559 (56.4%). We compared the rates of post‐PCI bleeding complications and 6‐month mortality. Results: The overall in‐hospital bleeding and 6‐month mortality rates were 4.6% and 11.8%, respectively. By multivariate logistic regression and after adjustment by propensity score analysis, bivalirudin was associated with a significant decrease in in‐hospital bleedings (HR = 0.41, 95% CI = 0.23–0.73, P = 0.003). By multivariate Cox analysis, bivalirudin was also associated with a significant decrease (HR = 0.6, 95% CI = 0.4–0.9, P = 0.01) and in‐hospital bleedings with a significant increase in the 6‐month mortality (HR = 2.5, 95% CI = 1.6–3.9, P < 0.001). Conclusion: This study suggests an important subset for use of bivalirudin in lieu of heparin that will benefit the very elderly. © 2009 Wiley‐Liss, Inc.